{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:51:19Z","timestamp":1790895079294,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,2]],"date-time":"2027-06-02T00:00:00Z","timestamp":1811894400000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.contraception.2025.111275","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:40:51Z","timestamp":1761928851000},"page":"111275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety of hormonal contraception among women with sickle cell disease: An updated systematic review"],"prefix":"10.1016","volume":"159","author":[{"given":"Antoinette T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetha","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea H.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia H.","family":"Pecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura K.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi K.","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2025.111275_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.hoc.2022.07.010","article-title":"Go the distance: reproductive health care for people with sickle cell disease","volume":"36","author":"Pecker","year":"2022","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1016\/j.contraception.2025.111275_bib2","unstructured":"Centers for Disease Control and Prevention. Data and statistics on sickle cell disease. 2024. \u3008https:\/\/www.cdc.gov\/sickle-cell\/data\/index.html\u3009 (accessed October 15, 2025)."},{"key":"10.1016\/j.contraception.2025.111275_bib3","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.contraception.2025.111275_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54545","article-title":"Comparisons of severe maternal morbidity and other adverse pregnancy outcomes in pregnant people with sickle cell disease vs anemia","volume":"6","author":"Early","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.contraception.2025.111275_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ajh.26818","article-title":"Pregnancy outcomes in women with sickle cell disease in California","volume":"98","author":"Adesina","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.contraception.2025.111275_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjmed.2012.12.016","article-title":"Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication","volume":"126","author":"Naik","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.contraception.2025.111275_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11239-013-0895-y","article-title":"Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know","volume":"35","author":"Naik","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.contraception.2025.111275_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12959-018-0179-z","article-title":"Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Noubiap","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.contraception.2025.111275_bib9","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3324\/haematol.2019.239350","article-title":"The molecular basis for the prothrombotic state in sickle cell disease","volume":"105","author":"Shet","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.contraception.2025.111275_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms","volume":"11","author":"Nath","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.contraception.2025.111275_bib11","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/jwh.2022.0046","article-title":"Sex as an independent risk factor for venous thromboembolism in sickle cell disease: a cross-sectional study","volume":"31","author":"Roe","year":"2022","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.contraception.2025.111275_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.14655","article-title":"Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality","volume":"178","author":"Brunson","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.contraception.2025.111275_bib13","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/jth.12744","article-title":"Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease","volume":"12","author":"Naik","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.contraception.2025.111275_bib14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.25508","article-title":"High incidence of venous thromboembolism recurrence in patients with sickle cell disease","volume":"94","author":"Brunson","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.contraception.2025.111275_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033278","article-title":"Incidence and risk factors for new and recurrent infarcts in adults with sickle cell disease","volume":"13","author":"Jordan","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.contraception.2025.111275_bib16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2016-01-694562","article-title":"Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia","volume":"127","author":"Kassim","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.contraception.2025.111275_bib17","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.contraception.2025.111275_bib18","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood.2023023031","article-title":"Rates of strokes in Californians with sickle cell disease in the post-STOP era","volume":"144","author":"Oluwole","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.contraception.2025.111275_bib19","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.111275_bib20","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3389\/fneur.2019.00993","article-title":"Oral contraceptive use and increased risk of stroke: a dose-response meta-analysis of observational studies","volume":"10","author":"Li","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.contraception.2025.111275_bib21","article-title":"Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke","volume":"2015","author":"Roach","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.111275_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.contraception.2016.10.005","article-title":"Nonoral combined hormonal contraceptives and thromboembolism: a systematic review","volume":"95","author":"Tepper","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/AOG.0000000000004896","article-title":"Association of progestogens and venous thromboembolism among women of reproductive age","volume":"140","author":"Cockrum","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.111275_bib24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/2047487318774847","article-title":"Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis","volume":"25","author":"Glisic","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.contraception.2025.111275_bib25","article-title":"Progestin-only contraception and thrombosis: an updated systematic review","author":"Tepper","year":"2025","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"Dragoman","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.contraception.2025.111275_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2006.12.018","article-title":"Range of published estimates of venous thromboembolism incidence in young women","volume":"75","author":"Heinemann","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1076029610368670","article-title":"Risk factors for heart attack, stroke, and venous thrombosis associated with hormonal contraceptive use","volume":"17","author":"Zakharova","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.contraception.2025.111275_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7304a1","article-title":"U.S. Medical Eligibility Criteria for Contraceptive Use, 2024","volume":"73","author":"Nguyen","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2025.111275_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.14423\/SMJ.0000000000000949","article-title":"Contraceptive methods and the impact of menstruation on daily functioning in women with sickle cell disease","volume":"112","author":"Day","year":"2019","journal-title":"South Med J"},{"key":"10.1016\/j.contraception.2025.111275_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.contraception.2021.08.009","article-title":"Contraceptive use and preferences among females with sickle cell disease","volume":"105","author":"Roe","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18041832","article-title":"Mechanisms of bone impairment in sickle bone disease","volume":"18","author":"Giordano","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.contraception.2025.111275_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2049463720920682","article-title":"Mechanisms of pain in sickle cell disease","volume":"15","author":"Takaoka","year":"2021","journal-title":"Br J Pain"},{"key":"10.1016\/j.contraception.2025.111275_bib34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.contraception.2011.10.008","article-title":"Contraception for individuals with sickle cell disease: a systematic review of the literature","volume":"85","author":"Haddad","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib35","article-title":"Steroid hormones for contraception in women with sickle cell disease","volume":"2007","author":"Manchikanti","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.111275_bib36","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/2151139a0","article-title":"Steroid hormones in sickle-cell disease","volume":"215","author":"Isaacs","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.contraception.2025.111275_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0960-0760(02)00266-2","article-title":"Binding of ovarian steroids to erythrocytes in patients with sickle cell disease; effects on cell sickling and osmotic fragility","volume":"84","author":"Yoong","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2025.111275_bib38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jbmr.3026","article-title":"Bone health in patients with hematopoietic disorders of bone marrow origin: systematic review and meta- analysis","volume":"32","author":"Steer","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.contraception.2025.111275_bib39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.20541","article-title":"High prevalence and correlates of low bone mineral density in young adults with sickle cell disease","volume":"81","author":"Miller","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.contraception.2025.111275_bib40","article-title":"Steroidal contraceptives and bone fractures in women: evidence from observational studies","volume":"2015","author":"Lopez","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.111275_bib41","unstructured":"Nguyen A., Curtis K., Whiteman M., Roe A., Pecker L., Naik R., et al. Hormonal contraception and risk of thrombosis among women with sickle cell disease and sickle cell trait: a systematic review. PROSPERO CRD 42022325257; 2022. \u3008https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42022320968\u3009 (accessed October 15, 2025)."},{"key":"10.1016\/j.contraception.2025.111275_bib42","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2025.111275_bib43","series-title":"Covidence systematic review software","year":"2023"},{"key":"10.1016\/j.contraception.2025.111275_bib44","article-title":"Chapter 25: Assessing risk of bias in a non-randomized study","volume":"2022","author":"Sterne","year":"2022"},{"key":"10.1016\/j.contraception.2025.111275_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.contraception.2025.111275_bib46","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2025.111275_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-0037-1604179","article-title":"Profile of reproductive issues associated with different sickle cell disease genotypes","volume":"39","author":"Carvalho","year":"2017","journal-title":"Rev Bras Ginecol Obstet"},{"key":"10.1016\/j.contraception.2025.111275_bib48","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0010-7824(97)00156-X","article-title":"Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients","volume":"56","author":"de Abood","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(82)90320-8","article-title":"Medroxyprogesterone acetate and homozygous sickle-cell disease","volume":"2","author":"De Ceulaer","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2025.111275_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27398","article-title":"A pilot study of hormonal contraceptive use and bone mineral density in young women with sickle cell disease","volume":"65","author":"Harrell","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.contraception.2025.111275_bib51","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1136\/bmj.306.6894.1735","article-title":"Contraceptives, counselling, and pregnancy in women with sickle cell disease","volume":"306","author":"Howard","year":"1993","journal-title":"Bmj"},{"key":"10.1016\/j.contraception.2025.111275_bib52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0009-9236(98)90074-1","article-title":"Nomegestrol acetate contraceptive implant use by women with sickle cell disease","volume":"64","author":"Nascimento","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2025.111275_bib53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.contraception.2010.06.017","article-title":"Hormonal contraception use and pregnancy in adolescents with sickle cell disease: analysis of Michigan Medicaid claims","volume":"83","author":"O'Brien","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.thromres.2015.04.013","article-title":"Oral contraceptive use and incident stroke in women with sickle cell disease","volume":"136","author":"Qureshi","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2025.111275_bib55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0020-7292(93)90159-T","article-title":"Norplant use by women with sickle cell disease","volume":"41","author":"Ladipo","year":"1993","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.contraception.2025.111275_bib56","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1046\/j.1365-2141.1999.01255.x","article-title":"Red cell deformability in oral contraceptive pill users with sickle cell anaemia","volume":"104","author":"Yoong","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.contraception.2025.111275_bib57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0010-7824(01)00202-5","article-title":"Carbohydrate metabolism in sickle cell patients using a subdermal implant containing nomegestrol acetate (Uniplant)","volume":"63","author":"Barbosa","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111275_bib58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1034\/j.1600-0609.2003.00061.x","article-title":"Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception","volume":"70","author":"Yoong","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.contraception.2025.111275_bib59","unstructured":"Centers for Disease Control and Prevention. Supplementary Appendix. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. 2024. \u3008https:\/\/stacks.cdc.gov\/view\/cdc\/156516\u3009 (accessed October 15, 2025)."},{"key":"10.1016\/j.contraception.2025.111275_bib60","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2023010204","article-title":"Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception","volume":"7","author":"Bala","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.contraception.2025.111275_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29877","article-title":"Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: a national survey","volume":"69","author":"Askew","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.contraception.2025.111275_bib62","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000003072","article-title":"ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.111275_bib63","doi-asserted-by":"crossref","first-page":"B17","DOI":"10.1016\/j.ajog.2023.10.031","article-title":"Society for Maternal-Fetal Medicine Consult Series #68: Sickle cell disease in pregnancy","volume":"230","author":"Sinkey","year":"2024","journal-title":"Am J Obstet Gynecol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425004664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425004664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:17:25Z","timestamp":1780712245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782425004664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"alternative-id":["S0010782425004664"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2025.111275","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of hormonal contraception among women with sickle cell disease: An updated systematic review","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2025.111275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111275"}}